Morningstar

City of Hope to Evaluate Quest Diagnostics' Haystack MRD® for Guiding Patient Management in Multiple Cancers

Fourteen City of Hope sites across the U.S. participating in research using the Haystack MRD ctDNA Test in patients with breast, colorectal, ovarian, and prostate cancer SECAUCUS, N.J. and LOS ANGELES ...
Morningstar

Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease Testing

Achieving the rigorous laboratory standard broadens access for providers and patients in New York; applies to use of Haystack MRD for patients with solid tumor cancers SECAUCUS, N.J., June 24, 2026 ...